167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
Masfarré L, Rocha P, Clavé S, Moliner L, Navarro-Gorro N, Ríos-Hoyo A, Sánchez I, Giner M, Corbera A, Taus A, Bellosillo B, Arriola E. 167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy. Annals Of Oncology 2022, 33: s109. DOI: 10.1016/j.annonc.2022.02.199.Peer-Reviewed Original Research